Replies to post #457772 on Anavex Life Sciences Corp (AVXL)

[frrol]

The past few years the EMA have had huge demand on their AD rapporteur roster. They're currently assessing lecanemab and donanemab, and they've been dragging on. Wouldn't be surprised if that was a factor in delay. Lecan is having procedural issues, and donan was being assessed for accelerated assessment last year (can't find out current status).

[Steady_T]

Thanks for the clarification.